Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-24-152/coif). B.D. is the current President of CGA-IGC, an organization focused on advancing the science and clinical management of hereditary GI cancer syndromes, including pancreatic cancer. It is a volunteer role. B.W.K. is a compensated advisory board member for Immunovia and has received clinical research funding paid to the institution from Janssen, Immunovia, Freenome, Guardant, Epigenomics, Universal Diagnostics, and Recursion. He receives support for his pancreatic cancer early detection research from multiple philanthropic and institutional sources. He currently serves as the Past President of CGA-IGC, which is a volunteer role. The authors have no other conflicts of interest to declare.